1.74
+2.35%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vickers Vantage Corp I
From its filings with the US Securities and Exchange Commission
Vickers Vantage Corp I is based in Palo Alto, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SCLX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $30.3m and a net loss of $374.1m. At that date it held total assets of $365.0m and shareholders' equity of −$207.8m.
We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.
Our commercial products are: (i) ZTlidoÒ (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia (“PHN”), which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) GLOPERBA®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, which launched in June 2024.
Quoted from its 10-K, filed 10 Apr 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 11 Jan 2021
- Employees
- 34
- Website
- scilexholding.com ↗
- Head office
- 960 SAN ANTONIO ROAD, PALO ALTO, CA, 94303
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Henry JiExecutive Chairman of the Board, President, Chief Executive Officer, since 2022$1.3m
- Mr. Stephen MaChief Financial Officer, Chief Operating Officer, Senior Vice President, Corporate Secretary, Director, since 2023$613,821
- Dr. Jay ChunIndependent Director$115,895
- Mr. Dorman FollowwillIndependent Director$301,945
- Dr. Yue WuIndependent Director$170,270
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ZTlido (lidocaine topical system) 1.8% treats postherpetic neuralgia pain effectively.
- Gloperba (colchicine USP) provides prophylactic treatment for gout flares in adults.
- SP-102 (SEMDEXA) is in Phase 3 for sciatica pain treatment.
Weaknesses
- Scilex Holding Co. has only 34 employees, which is low for a pharmaceutical company.
- The company's IPO was on 11 January 2021, indicating recent market entry.
- Scilex Holding Co. employs 109 full-time employees, which is below industry standards.
Opportunities
- SP-103 5.4% is in Phase 2 for low back pain treatment expansion.
- SP-104 DBR-LDN Capsule targets chronic pain and fibromyalgia in multiple Phase 1 programs.
- The firm's focus on non-opioid pain management aligns with current healthcare trends.
Threats
- The pharmaceutical industry faces intense competition from established players.
- Regulatory approvals for new products may delay market entry.
- Market acceptance of non-opioid pain management products is uncertain.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.